Vadimezan
| Clinical data | |
|---|---|
| Other names | ASA404, DMXAA |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.107.097 |
| Chemical and physical data | |
| Formula | C17H14O4 |
| Molar mass | 282.295 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Vadimezan (also known as or ASA404 and dimethylxanthenone acetic acid or DMXAA) is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.